Cyclo-oxygenase 2: A pharmacological target for the prevention of cancer

Lancet Oncology

Volumn 2, Issue 9, 2001, Pages 544-551

  Dannenberg, Andrew J ^a   Altorki, Nasser K ^a   Boyle, Jay O ^b   Dang, Chau ^b   Howe, Louise R ^a   Weksler, Babette B ^a   Subbaramaiah, Kotha ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2; ISOENZYME; MEMBRANE PROTEIN; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; PTGS2 PROTEIN, HUMAN; XENOBIOTIC AGENT;

APOPTOSIS; BIOSYNTHESIS; CANCER INVASION; DRUG ANTAGONISM; ENZYMOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CYCLOOXYGENASE 2; HUMANS; IMMUNOSUPPRESSION; INFLAMMATION; ISOENZYMES; MEMBRANE PROTEINS; NEOPLASM INVASIVENESS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; XENOBIOTICS;

EID: 0035468642     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(01)00488-0     Document Type: Review

References (90)

1. Thun M.J., Namboodiri M.M., HeathJr C.W. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 325:1991;1593-1596.
2. Schreinemachers D.M., Everson R.B. Aspirin use and lung, colon and breast cancer incidence in a prospective study. Epidemiology. 5:1994;138-146.
3. Farrow D.C., Vaughan T.L., Hansten P.D., et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev. 7:1998;97-102.
4. Langman M.J., Cheng K.K., Gilman E.A., et al. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ. 320:2000;1642-1646.
5. Reddy B.S., Maruyama H., Kelloff G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumour development. Cancer Res. 47:1987;5340-5346.
6. McCormick D.L., Moon R.C. Inhibition of mammary carcinogenesis by flurbiprofen, a non-steroidal antiinflammatory agent. Br J Cancer. 48:1983;859-861.
7. Cornwall H., Odukoya O., Shklar G. Oral mucosal tumor inhibition by ibuprofen. J Oral Maxillofac Surg. 41:1983;795-800.
8. Castonguay A., Rioux N. Inhibition of lung tumorigenesis by sulindac: comparison of two experimental protocols. Carcinogenesis. 18:1997;491-496.
9. Rubio C.A. Antitumoral activity of indomethacin on experimental esophageal tumors. J Natl Cancer Inst. 72:1984;705-707.
10. Moon R.C., Kelloff G.J., Detrisac C.J., et al. Chemoprevention of OH-BBN-induced bladder cancer in mice by piroxicam. Carcinogenesis. 14:1993;1487-1489.
11. Ben-Av P., Crofford L.J., Wilder R.L., et al. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett. 372:1995;83-87.
12. Masferrer J.L., Leahy K.M., Koki A.T., et al. Antiangiogenic and antitumour activities of cyclooxygenase-2 inhibitors. Cancer Res. 60:2000;1306-1311.
13. Langman M.J., Jensen D.M., Watson D.J., et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA. 282:1999;1929-1933.
14. Silverstein F.E., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. JAMA. 284:2000;1247-1255.
15. Funk C.D., Funk L.B., Kennedy M.E., et al. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J. 5:1991;2304-2312.
16. Herschman H.R. Prostaglandin synthase 2. Biochim Biophys Acta. 1299:1996;125-140.
17. Subbaramaiah K., Telang N., Ramonetti J.T., et al. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res. 56:1996;4424-4429.
18. Inoue H., Yokoyama C., Hara S., et al. Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of both nuclear factor for interleukin-6 expression site and cAMP response element. J Biol Chem. 270:1995;24965-24971.
19. Sheng H., Shao J., Dixon D.A., et al. Transforming growth factor-b1 enhances Ha-RAS-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. J Biol Chem. 275:2000;6628-6635.
20. Kurumbail R.G., Stevens A.M., Gierse J.K., et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature. 384:1996;644-648.
21. Eberhart C.E., Coffey R.J., Radhika A., et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 107:1994;1183-1188.
22. Sung J.J.Y., Leung W.K., Go M.Y.Y., et al. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am J Pathol. 157:2000;729-735.
23. Ristimaki A., Honkanen N., Jankala H., et al. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 57:1997;1276-1280.
24. Wilson K.T., Fu S., Ramanujam K., et al. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res. 58:1998;2929-2934.
25. Zimmermann K.C., Sarbia M., Weber A.A., et al. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res. 59:1999;198-204.
26. Kondo M., Yamamoto H., Nagano H., et al. Increased expression of COX 2 in nontumour liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clin Cancer Res. 5:1999;4005-4012.
27. Koga H., Sakisaka S., Ohishi M., et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumour dedifferentiation. Hepatology. 29:1999;688-696.
28. Tucker O.N., Dannenberg A.J., Yang E.K., et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 59:1999;987-990.
29. Chan G., Boyle J.O., Yang E.K., et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res. 59:1999;991-994.
30. Wolff H., Saukkonen K., Anttila S., et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 58:1998;4997-5001.
31. Soslow R.A., Dannenberg A.J., Rush D., et al. COX 2 is expressed in human pulmonary, colonic and mammary tumours. Cancer. 89:2000;2637-2645.
32. Parrett M.L., Harris R.E., Joarder F.S., et al. Cyclooxygenase-2 gene expression in human breast cancer. Int J Oncol. 10:1997;503-507.
33. Uotila P., Valve E., Martikainen P., et al. Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol Res. 29:2001;23-28.
34. Gupta S., Srivastava M., Ahmad N., et al. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate. 42:2000;73-78.
35. Shirahama T. Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin Cancer Res. 6:2000;2424-2430.
36. Mohammed S.I., Knapp D.W., Bostwick D.G., et al. Expression of cyclooxygenase-2 (COX 2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res. 59:1999;5647-5650.
37. Kulkarni S., Rader J.S., Zhang F., et al. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res. 7:2001;429-434.
38. Tong B.J., Tan J., Tajeda L., et al. Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-d in human endometrial adenocarcinoma. Neoplasia. 2:2000;483-490.
39. Muller-Decker K., Reinerth G., Krieg P., et al. Prostaglandin-H synthase isozyme expression in normal and neoplastic human skin. Int J Cancer. 82:1999;648-656.
40. Buckman S.Y., Gresham A., Hale P., et al. COX 2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis. 19:1998;723-729.
41. Joki T., Heese O., Nikas D.C., et al. Expression of cyclooxygenase 2 (COX 2) in human glioma and in vitro inhibition by a specific COX 2 inhibitor, NS-398. Cancer Res. 60:2000;4926-4931.
42. Zhang F., Subbaramaiah K., Altorki N., et al. Dihydroxy bile acids activate the transcription of cyclooxygenase-2. J Biol Chem. 273:1998;2424-2428.
43. Subbaramaiah K., Altorki N., Chung W.J., et al. Inhibition of cyclooxygenase-2 gene expression by P53. J Biol Chem. 274:1999;10911-10915.
44. Leung W.K., To K.-F., Ng Y.P., et al. Association between cyclo-oxygenase2 overexpression and missense P53 mutations in gastric cancer. Br J Cancer. 84:2001;335-339.
45. Liu C.H., Chang S.-H., Narko K., et al. Over-expression of cyclooxygenase (Cox)-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem. 276:2001;18563-18569.
46. ?716 knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell. 87:1996;803-809.
47. Tiano H., Chulada P., Spalding J., et al. Effects of cyclooxygenase deficiency on inflammation and papilloma development in mouse skin. Proc Am Assoc Cancer Res. 38:1997;257.
48. Chulada P.C., Thompson M.B., Mahler J.F., et al. Genetic disruption of Ptgs-1, as well as of Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res. 60:2000;4705-4708.
49. Kawamori T., Rao C.V., Seibert K., et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 58:1998;409-412.
50. Jacoby R.F., Seibert K., Cole C.E., et al. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the Min mouse model of adenomatous polyposis. Cancer Res. 60:2000;5040-5044.
51. Δ716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res. 61:2001;1733-1740.
52. Harris R.E., Alshafie G.A., Abou-Issa H., et al. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res. 60:2000;2101-2103.
53. Fischer S.M., Lo H.H., Gordon G.B., et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog. 25:1999;231-240.
54. Rioux N., Castonguay A. Prevention of NNK-induced lung tumourigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res. 58:1998;5354-5360.
55. Grubbs C.J., Lubet R.A., Koki A.T., et al. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res. 60:2000;5599-5602.
56. Shiotani H., Denda A., Yamamoto K., et al. Increased expression of cyclooxygenase-2 protein and 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide. Cancer Res. 61:2001;1451-1456.
57. Nishimura G., Yanoma S., Mizuno H., et al. A selective cyclooxygenase-2 inhibitor suppresses tumour growth in nude mouse xenografted with human head and neck squamous carcinoma cells. Jpn J Cancer Res. 90:1999;1152-1162.
58. Sheng H., Shao J., Kirkland S.C., et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest. 99:1997;2254-2259.
59. Sawaoka H., Kawano S., Tsuji S., et al. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol. 274:1998;G1061-G1067.
60. Stolina M., Sharma S., Lin Y., et al. Specific inhibition of cyclooxygenase-2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol. 164:2000;361-370.
61. Alshafie G.A., Abou-Issa H.M., Seibert K., et al. Chemotherapeutic evaluation of celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumour model. Oncol Rep. 7:2000;1377-1381.
62. Liu X.H., Kirschenbaum A., Yao S., et al. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol. 164:2000;820-825.
63. Marx J. Anti-inflammatories inhibit cancer growth-but how. Science. 291:2001;581-582.
64. Zhang X., Morham S.G., Langenbach R., et al. Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med. 190:1999;451-459.
65. Williams C.S., Watson A.J.M., Sheng H., et al. Celecoxib prevents tumour growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res. 60:2000;6045-6051.
66. Eling T.E., Thompson D.C., Foureman G.L., et al. Prostaglandin H synthase and xenobiotic oxidation. Annu Rev Pharmacol Toxicol. 30:1990;1-45.
67. Wiese F.M., Thompson P.A., Kadlubar F.F. Carcinogen substrate specificity of human COX 1 and COX 2. Carcinogenesis. 22:2001;5-10.
68. Plastaras J.P., Guengerich F.P., Nebert D.W., et al. Xenobiotic-metabolizing cytochromes P450 convert prostaglandin endoperoxide to hydroxyheptadecatrienoic acid and the mutagen, malondialdehyde. J Biol Chem. 275:2000;11784-11790.
69. Kelley D.J., Mestre J.R., Subbaramaiah K., et al. Benzo[a]pyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells. Carcinogenesis. 18:1997;795-799.
70. Tsujii M., Kawano S., Tsuji S., et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 93:1998;705-716.
71. Williams C.S., Tsujii M., Reese J., et al. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest. 105:2000;1589-1594.
72. Tsujii M., DuBois R.N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cell. 83:1995;493-501.
73. Weitzman S.A., Gordon L.I. Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. Blood. 76:1990;655-663.
74. Balch C.M., Dougherty P.A., Cloud G.A., et al. Prostaglandin E2-mediated suppression of cellular immunity in colon cancer patients. Surgery. 95:1984;71-77.
75. Kambayashi T., Alexander A.R., Fong M., et al. Potential involvement of IL-10 in suppressing tumour-associated macrophages. Colon-26-derived prostaglandin E2 inhibits TNF-alpha release via a mechanism involving IL-10. J Immunol. 154:1995;3383-3390.
76. Plescia O.J., Smith A.H., Grinwich K. Subversion of immune system by tumor cells and role of prostaglandins. Proc Natl Acad Sci USA. 72:1975;1848-1851.
77. Tsujii M., Kawano S., DuBois R.N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA. 94:1997;3336-3340.
78. Dohadwala M., Luo J., Zhu L., et al. Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem. 276:2001;20809-20812.
79. Tomozawa S., Nagawa H., Tsuno N., et al. Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX 2 inhibitor, JTE-522. Br J Cancer. 81:1999;1274-1279.
80. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med. 105:(suppl 1B):1998;31S-38.
81. Petersen G.M., Slack J., Nakamura Y. Screening guidelines and premorbid diagnosis of familial adenomatous polyposis using linkage. Gastroenterology. 100:1991;1658-1664.
82. Giardiello F.M., Hamilton S.R., Krush A.J., et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 328:1993;1313-1316.
83. Steinbach G., Lynch P.M., Phillips R.K.S., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 342:2000;1946-1952.
84. Rivers J.K., McLean D.I. An open study to assess the efficacy and safety of topical 3% diclofenac in 2.5% hyaluronic acid gel for the treatment of actinic keratoses. Arch Dermatol. 133:1997;1239-1242.
85. Meyskens F.L., Gerner E.W., Emerson S., et al. Effect of a-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention. J Natl Cancer Inst. 90:1998;1212-1218.
86. Jacoby R.F., Cole C.E., Tutsch K., et al. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Res. 60:2000;1864-1870.
87. Torrance C.J., Jackson P.E., Montgomery E., et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med. 6:2000;1024-1028.
88. Zhao Y., Agarwal V.R., Mendelson C.R., et al. Estrogen biosynthesis proximal to a breast tumour is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology. 137:1996;5739-5742.
89. Moore R.J., Zweifel B.S., Heuvelman D.M., et al. Enhanced antitumour activity by co-administration of celecoxib and the chemotherapeutic agents cyclophosphamide and 5-FU. Proc Am Assoc Cancer Res. 41:2000;409.
90. Milas L., Kishi K., Hunter N., et al. Enhancement of tumour response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst. 91:1999;1501-1504.